Description

Bullfrog AI Holdings, Inc., along with its various subsidiaries, operates as a digital biopharmaceutical company. Its core business involves leveraging artificial intelligence (AI) and machine learning (ML) to meticulously analyze medical and healthcare datasets within the United States. The company's proprietary offering, bfLEAP, is an advanced AI/ML platform specifically designed for processing and interpreting both preclinical and clinical research data. Furthermore, Bullfrog AI has secured significant licensing agreements. One agreement with George Washington University grants them the rights to employ siRNA (small interfering RNA) targeting Beta2-spectrin for treating diverse human conditions, including but not limited to hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Another key accord with Johns Hopkins University authorizes the use of a specialized Mebendazole formulation for the therapeutic treatment of human cancers or other neoplastic diseases. Founded in 2017, Bullfrog AI Holdings, Inc. is headquartered in Gaithersburg, Maryland.